CClinicalTrials.gg
Sign In
CompletedNCT04719234Updated Jan 22, 2021

Lung Ultrasonography in COVID-19 Pneumonia

An interventional study of lung ultrasonography in Lung Ultrasound, Pneumonia and Covid19, sponsored by Bursa Yüksek İhtisas Education and Research Hospital. Completed at 1 site in Turkey. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-01-22.

Sponsored by Bursa Yüksek İhtisas Education and Research Hospital · Not applicable, Interventional, and Diagnostic

From the registry’s dates

  • Registered 7 months after the study started (first participant enrolled Jun 2020, registered Jan 2021).
Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Lung ultrasonography has been used for diagnosis and treatment in many departments including intensive care before the pandemic. The gold standard method for the diagnosis of pneumonia is still chest tomography. Ultrasonography, which has advantages over tomography, has also been tried to be used in covid 19 pneumonia.

Read the detailed description

In this study, it was aimed to investigate the efficiency of lung ultrasonography in diagnosis of covid 19 pneumonia.

02

Conditions studied

  • Lung Ultrasound
  • Pneumonia
  • Covid19
03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's enrollment of 60 is below the median of 100 across 4,098 interventional studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

Bursa Yüksek İhtisas Education and Research Hospital is the lead sponsor of 62 studies on the registry; 3 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • 18 and 85 years old
  • Hospitalized in intensive care unit
  • PCR tested
  • Thoracic CT applied

Exclusion criteria

Exclusion Criteria:

  • Previous lung and thoracic wall surgery
  • Anatomically with thoracic wall disorder
  • Patients who did not consent to participate in the study
05

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Other
    lung ultrasound

    lung ultrasonography protocol will be applied.

    Device: lung ultrasonography

Interventions

  • Devicelung ultrasonography

    Application of 12 zone lung ultrasonography protocol using the konvex ultrasound probe (2-6 MHz)

06

What researchers measure

Primary outcomes

  1. Relationship between Thoracic CT imaging results and LUS results

    Lung ultrasonography will be performed within 6 hours of the Thoracic CT.

    Time frame: 6 hours

Secondary outcomes

  1. Characteristics of lesions

    İdentifying the characteristics of the abnormal findings detected in Thoracic CT and LUS

    Time frame: 6 hours

Other outcomes

  1. the relation of the lesions with the pleura

    the relation of the lesions with the pleura, and their distance to the pleura.

    Time frame: 6 hours

07

Study locations

1 site
  • University of Health Sciences, Bursa Yuksek Ihtisas Training and Research Hospital
    Bursa, Turkey
08

References and documents

Publications

  • Okmen K, Yildiz DK, Soyaslan E. Comparison of lung ultrasonography findings with chest computed tomography results in coronavirus (COVID-19) pneumonia. J Med Ultrason (2001). 2021 Apr;48(2):245-252. doi: 10.1007/s10396-021-01081-7. Epub 2021 Feb 26. PubMed 33638057 ↗

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 22, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04719234
Lead sponsor
Bursa Yüksek İhtisas Education and Research Hospital
Responsible party
Korgün Ökmen (Principal Investigator ,Assoc. PhD. M.D., Bursa Yüksek İhtisas Education and Research Hospital) — Principal investigator
First posted
Jan 22, 2021
Start date
Jun 15, 2020
Primary completion
Dec 1, 2020
Completion
Dec 1, 2020
Last update
Jan 22, 2021

Study contacts

Korgün Ökmen, Assoc. PhD.
principal investigator · Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi
Durdu Kahraman Yıldız, M.D
study chair · Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi
Emel Tatar Soyaslan, M.D
study chair · Sağlık Bilimleri Üniversitesi Bursa Yüksek İhtisas Eğitim Ve Araştırma Hastanesi

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

COVID-19→

Other studies from this sponsor

Bursa Yüksek İhtisas Education and Research Hospital

Start the discussion